Douglas G Ward

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3510079/publications.pdf

Version: 2024-02-01

81 papers	2,566 citations	159358 30 h-index	205818 48 g-index
81 all docs	81 docs citations	81 times ranked	3931 citing authors

#	Article	IF	Citations
1	Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. European Urology Oncology, 2023, 6, 67-75.	2.6	12
2	STAG2 Protein Expression in Nonâ€“muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. European Urology Open Science, 2022, 38, 88-95.	0.2	3
3	Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. Genome Medicine, 2022, 14, .	3.6	5
4	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	5.8	159
5	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. Translational Andrology and Urology, 2021, 10, 2787-2808.	0.6	7
6	Urine DNA for monitoring chemoradiotherapy response in muscleâ€invasive bladder cancer: a pilot study. BJU International, 2021, , .	1.3	3
7	The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 11150.	1.8	10
8	Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. European Journal of Cancer, 2021, 158, 191-207.	1.3	17
9	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. Frontiers in Oncology, 2020, 10, 812.	1.3	11
10	Targeted deep sequencing of urothelial bladder cancers and associated urinary <scp>DNA</scp>: a 23â€gene panel with utility for nonâ€invasive diagnosis and risk stratification. BJU International, 2019, 124, 532-544.	1.3	47
11	Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. International Journal of Molecular Sciences, 2019, 20, 1102.	1.8	7
12	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 2019, 5, 263-272.	0.2	10
13	The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. Journal of General Physiology, 2019, 151, 18-29.	0.9	25
14	A potential role for hepcidin in obesity-driven colorectal tumourigenesis. Oncology Reports, 2018, 39, 392-400.	1.2	6
15	Globotriaosylsphingosine (Lysoâ€Gb₃) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 2018, 41, 239-247.	1.7	25
16	Structural investigation of hemicelluloses from Plantago ovata, Mimosa pudica and Lallemantia royleana by MALDI-ToF mass spectrometry. Journal of Carbohydrate Chemistry, 2018, 37, 285-301.	0.4	9
17	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228â€SG>A/T Mutation. Bladder Cancer, 2018, 4, 41-48.	0.2	40
18	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Scientific Reports, 2018, 8, 11290.	1.6	28

#	Article	IF	Citations
19	Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma. Neoplasia, 2017, 19, 165-174.	2.3	10
20	Liquid biopsies for bladder cancer. Translational Andrology and Urology, 2017, 6, 331-335.	0.6	33
21	Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. Journal of Crohn's and Colitis, 2016, 11, jjw208.	0.6	13
22	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. Bladder Cancer, 2016, 2, 301-317.	0.2	79
23	Integrative topological analysis of mass spectrometry data reveals molecular features with clinical relevance in esophageal squamous cell carcinoma. Scientific Reports, 2016, 6, 21586.	1.6	6
24	A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients. Journal of the American Society for Mass Spectrometry, 2016, 27, 719-725.	1.2	7
25	Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca2+-sensitivity and suppress the modulation of Ca2+-sensitivity by troponin I phosphorylation. Archives of Biochemistry and Biophysics, 2016, 601, 113-120.	1.4	49
26	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. European Journal of Human Genetics, 2016, 24, 1167-1174.	1.4	115
27	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.	1.1	66
28	Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. Proteomes, 2015, 3, 266-282.	1.7	5
29	Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. British Journal of Cancer, 2015, 112, 1052-1058.	2.9	36
30	Robust twin boosting for feature selection from high-dimensional omics data with label noise. Information Sciences, 2015, 291, 1-18.	4.0	32
31	Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. Journal of Nephrology, 2015, 28, 81-88.	0.9	10
32	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. British Journal of Cancer, 2014, 110, 2277-2282.	2.9	9
33	Estimation of polyclonal Ig<scp>G</scp>4 hybrids in normal human serum. Immunology, 2014, 142, 406-413.	2.0	23
34	Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. British Journal of Cancer, 2014, 110, 679-685.	2.9	35
35	Proteomic profiling of <scp>N</scp>â€linked glycoproteins identifies <scp>C</scp>on<scp>A</scp>â€binding procathepsin <scp>D</scp> as a novel serum biomarker for hepatocellular carcinoma. Proteomics, 2014, 14, 186-195.	1.3	14
36	Tropomyosin isoform expression and phosphorylation in the human heart in health and disease. Journal of Muscle Research and Cell Motility, 2013, 34, 189-197.	0.9	25

#	Article	IF	Citations
37	Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. British Journal of Cancer, 2013, 108, 1854-1861.	2.9	41
38	Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity. Cardiovascular Research, 2013, 99, 65-73.	1.8	68
39	MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers. Journal of Proteomics, 2013, 80, 207-215.	1.2	15
40	Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. European Journal of Cancer, 2013, 49, 2214-2222.	1.3	41
41	Myofibrillar Ca2+ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T. Cardiovascular Research, 2013, 97, 500-508.	1.8	34
42	Z-band Alternatively Spliced PDZ Motif Protein (ZASP) Is the Major O-Linked Î²-N-Acetylglucosamine-substituted Protein in Human Heart Myofibrils. Journal of Biological Chemistry, 2013, 288, 4891-4898.	1.6	12
43	Analysis of premalignant pancreatic cancer mass spectrometry data for biomarker selection using a group search optimizer. Transactions of the Institute of Measurement and Control, 2012, 34, 668-676.	1.1	13
44	Structural Basis of Ligand Interactions of the Large Extracellular Domain of Tetraspanin CD81. Journal of Virology, 2012, 86, 9606-9616.	1.5	42
45	Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules, and Diseases, 2012, 48, 233-237.	0.6	33
46	Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas. British Journal of Cancer, 2012, 107, 1595-1601.	2.9	14
47	The effect of carbohydrate ingestion on plasma interleukin-6, hepcidin and iron concentrations following prolonged exercise. Cytokine, 2011, 53, 196-200.	1.4	51
48	Assessment of highâ€throughput highâ€resolution MALDIâ€TOFâ€MS of urinary peptides for the detection of muscleâ€invasive bladder cancer. Proteomics - Clinical Applications, 2011, 5, 493-503.	0.8	29
49	Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomarkers, 2011, 7, 123-132.	0.8	23
50	Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers. Interactive Cardiovascular and Thoracic Surgery, 2011, 13, 3-6.	0.5	2
51	Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen. European Journal of Gastroenterology and Hepatology, 2010, 22, 1358-1363.	0.8	7
52	Characterization of the transition-metal-binding properties of hepcidin. Biochemical Journal, 2010, 427, 289-296.	1.7	35
53	10 Years of SELDI: What Have we Learnt?. Current Proteomics, 2010, 7, 15-25.	0.1	6
54	Identification of macrophage migration inhibitory factor and human neutrophil peptides 1â€“3 as potential biomarkers for gastric cancer. British Journal of Cancer, 2009, 101, 295-302.	2.9	45

#	Article	IF	Citations
55	Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle. Circulation: Heart Failure, 2009, 2, 456-464.	1.6	46
56	Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery. Clinical Proteomics, 2009, 5, 148-155.	1.1	2
57	Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica, 2009, 94, 1748-1752.	1.7	161
58	Is iron overload in alcohol-related cirrhosis mediated byhepcidin?. World Journal of Gastroenterology, 2009, 15, 5864.	1.4	14
59	Proteomic profiling of urine for the detection of colon cancer. Proteome Science, 2008, 6, 19.	0.7	56
60	SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Science, 2008, 6, 28.	0.7	60
61	Increased hepcidin expression in colorectal carcinogenesis. World Journal of Gastroenterology, 2008, 14, 1339.	1.4	87
62	Plasma Proteome Analysis Reveals the Geographical Origin and Liver Tumor Status of Dab (Limanda) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	4.6	30
63	TNP-8N3-ADP Photoaffinity Labeling of Two Na,K-ATPase Sequences under Separate Na+ plus K+ Control. Biochemistry, 2006, 45, 3460-3471.	1.2	4
64	Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. British Journal of Cancer, 2006, 94, 287-292.	2.9	62
65	Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer, 2006, 94, 1898-1905.	2.9	198
66	Preclinical and post-treatment changes in the HCC-associated serum proteome. British Journal of Cancer, 2006, 95, 1379-1383.	2.9	27
67	Liver Tumors in Wild Flatfish: A Histopathological, Proteomic, and Metabolomic Study. OMICS A Journal of Integrative Biology, 2005, 9, 281-299.	1.0	82
68	Characterization of the Interaction between the N-Terminal Extension of Human Cardiac Troponin I and Troponin Câ€. Biochemistry, 2004, 43, 4020-4027.	1.2	32
69	NMR and Mutagenesis Studies on the Phosphorylation Region of Human Cardiac Troponin I. Biochemistry, 2004, 43, 5772-5781.	1.2	29
70	A Cross-Linking Study of the N-Terminal Extension of Human Cardiac Troponin Iâ€. Biochemistry, 2003, 42, 10324-10332.	1.2	28
71	Inactivation of Na,K-ATPase Following Co(NH3)4ATP Binding at a Low Affinity Site in the Protomeric Enzyme Unit. Journal of Biological Chemistry, 2003, 278, 14688-14697.	1.6	6
72	Structural Consequences of Cardiac Troponin I Phosphorylation. Journal of Biological Chemistry, 2002, 277, 41795-41801.	1.6	26

#	Article	IF	Citations
73	Calcium and Peptide Binding to Folded and Unfolded Conformations of Cardiac Troponin C. Electrospray Ionization and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. European Journal of Mass Spectrometry, 2002, 8, 471-481.	0.5	7
74	Additional PKA phosphorylation sites in human cardiac troponinâ€ƒI. FEBS Journal, 2001, 268, 179-185.	0.2	18
75	The Importance of the Carboxyl-terminal Domain of Cardiac Troponin C in Ca2+-sensitive Muscle Regulation. Journal of Biological Chemistry, 2000, 275, 32508-32515.	1.6	23
76	Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2â€²(3â€²)-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5â€²-Diphosphate. Journal of Biological Chemistry, 1998, 273, 14277-14284.	1.6	17
77	Affinity Labeling of Two Nucleotide Sites on Na,K-ATPase Using 2â€²(3â€²)-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5â€²-[Î±-32P]Diphosphate (TNP-8N3-[Î±-32P]ADP) as a Photoactivatable Probe. Journal of Biological Chemistry, 1998, 273, 33759-33765.	1.6	19
78	K+Induces an Acid-Labile Phosphoenzyme (or an Occluded PiForm) in Na,K-ATPase. Annals of the New York Academy of Sciences, 1997, 834, 381-385.	1.8	0
79	Nucleotides Trigger the Release of Co(NH3)4ATP Tightly Bound to Inactivated Na,K-ATPase. Annals of the New York Academy of Sciences, 1997, 834, 432-434.	1.8	0
80	Binding of 2â€²(3â€²)-O-(2,4,6-Trinitrophenyl)ADP to Soluble Î±Î² Protomers of Na,K-ATPase Modified with Fluorescein Isothiocyanate. Journal of Biological Chemistry, 1996, 271, 12317-12321.	1.6	30
81	Irreversible effects of calcium ions on the plasma membrane calcium pump. Journal of Membrane Biology, 1993, 136, 313-26.	1.0	0